Heart Transplant Rejection
0
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
NateraAUSTIN, TX
2 programsMMDx diagnostic testN/A1 trial
Prospera Test Evaluation in Cardiac Transplant (ProTECT)N/A1 trial
Active Trials
Angeles TherapeuticsCA - Los Angeles
1 programNano-Heart tool: Intra-Graft Targeted Gene Expression ProfilingN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Angeles TherapeuticsNano-Heart tool: Intra-Graft Targeted Gene Expression Profiling
NateraProspera Test Evaluation in Cardiac Transplant (ProTECT)
NateraMMDx diagnostic test
Clinical Trials (3)
Total enrollment: 1,207 patients across 3 trials
Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.
Start: Nov 2021Est. completion: Dec 2023496 patients
N/ACompleted
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
Start: Oct 2021Est. completion: Jun 2027411 patients
N/AActive Not Recruiting
Trifecta-Heart cfDNA-MMDx Study
Start: Jun 2021Est. completion: Jul 2027300 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 1,207 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.